Status and phase
Conditions
Treatments
About
This study aimed to evaluate the use of SHR-A1811 and bevacizumab in HER2-positive Breast Cancer with brain metastases
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Previous treatment with trastuzumab deruxtecan (DS-8201a) or any other antibody drug conjugate (ADC) which consists of an exatecan derivative that is a topoisomerase 1 inhibitor;
Previous treatment with bevacizumab;
Participated in other drug clinical trials within 4 weeks before admission;
History of clinically significant lung disease;
Other malignant tumors, excluding cured cervical carcinoma in situ, skin basal cell carcinoma or skin squamous cell carcinoma, have been diagnosed in the past five years.
According to the judgement of the researchers, there are concomitant diseases that seriously endanger the safety of patients or affect the completion of research (including, but not limited to, severe hypertension, severe diabetes, active infections, etc.).
Any other conditions that researchers believe that patients are unsuitable for this study.
Primary purpose
Allocation
Interventional model
Masking
30 participants in 1 patient group
Loading...
Central trial contact
Xiong huihua
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal